Cytosorbents (CTSO) vs HeartSciences (HSCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HeartSciences (HSCS) has outperformed Cytosorbents (CTSO) over the past year, losing 18.3% versus a loss of 80.9%. HeartSciences is the larger company by market cap ($14.7 million vs $11.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | HSCS |
|---|---|---|
| Share price | $3.73 | $3.04 |
| Market cap | $11.75M | $14.73M |
| 1-day change | -3.62% | -12.89% |
| YTD return | -70.81% | -1.62% |
| 1-year return | -80.87% | -18.28% |
| 5-year return | -96.82% | — |
| EPS (TTM) | $-5.80 | $-3.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.72 | $5.25 |
| 52-week low | $3.66 | $1.63 |
| Distance from 52-week high | -81.09% | -42.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1173.46% | +294.74% |
| Average volume | 12.45K | 154.08K |
| Shares outstanding | 3.15M | 4.84M |
| Employees | 129 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HSCS has outperformed CTSO by 62.6 percentage points over the past year.
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
About HeartSciences
HSCS stock →HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.
Healthcare · Medical Devices · 14 employees
CTSO vs HSCS FAQ
Which is bigger, Cytosorbents or HeartSciences?
HeartSciences (HSCS) is larger, with a market capitalization of $14.73M compared with $11.75M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CTSO or HSCS?
HSCS returned -18.28% over the past 12 months, compared with -80.87% for CTSO (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and HeartSciences in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.